Replimune Group (NASDAQ:REPL) Rating Lowered to Strong Sell at Wall Street Zen
by Amy Steele · The Cerbat GemReplimune Group (NASDAQ:REPL – Get Free Report) was downgraded by investment analysts at Wall Street Zen from a “sell” rating to a “strong sell” rating in a research note issued to investors on Saturday.
REPL has been the subject of several other research reports. BMO Capital Markets lowered Replimune Group from a “market perform” rating to an “underperform” rating in a report on Monday, April 13th. Leerink Partners reaffirmed a “market perform” rating and set a $2.00 price target (down from $11.00) on shares of Replimune Group in a research report on Monday, April 13th. Jefferies Financial Group reissued a “hold” rating and issued a $2.00 price objective (down from $13.00) on shares of Replimune Group in a report on Monday, April 13th. Piper Sandler cut shares of Replimune Group from an “overweight” rating to a “neutral” rating and set a $4.00 target price for the company. in a report on Friday, April 10th. Finally, JPMorgan Chase & Co. reiterated an “underweight” rating on shares of Replimune Group in a research note on Monday, April 13th. Six investment analysts have rated the stock with a Hold rating and four have given a Sell rating to the company’s stock. Based on data from MarketBeat, Replimune Group has an average rating of “Reduce” and a consensus price target of $4.75.
Read Our Latest Report on Replimune Group
Replimune Group Stock Performance
Replimune Group stock opened at $2.42 on Friday. The stock has a market cap of $199.82 million, a price-to-earnings ratio of -0.70 and a beta of 0.74. The stock’s 50 day simple moving average is $6.44 and its two-hundred day simple moving average is $7.79. Replimune Group has a fifty-two week low of $1.50 and a fifty-two week high of $13.24. The company has a debt-to-equity ratio of 0.33, a quick ratio of 5.60 and a current ratio of 5.60.
Replimune Group (NASDAQ:REPL – Get Free Report) last issued its quarterly earnings results on Tuesday, February 3rd. The company reported ($0.77) EPS for the quarter, topping analysts’ consensus estimates of ($0.85) by $0.08. As a group, analysts expect that Replimune Group will post -3.39 earnings per share for the current fiscal year.
Insider Transactions at Replimune Group
In other news, insider Christopher Sarchi sold 6,500 shares of Replimune Group stock in a transaction that occurred on Thursday, April 2nd. The shares were sold at an average price of $8.01, for a total transaction of $52,065.00. Following the sale, the insider owned 151,588 shares in the company, valued at $1,214,219.88. This trade represents a 4.11% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 5.20% of the stock is currently owned by company insiders.
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently made changes to their positions in the stock. SG Americas Securities LLC increased its holdings in shares of Replimune Group by 110.8% in the first quarter. SG Americas Securities LLC now owns 151,674 shares of the company’s stock worth $1,160,000 after purchasing an additional 79,719 shares during the last quarter. Invesco Ltd. grew its holdings in Replimune Group by 297.3% during the 4th quarter. Invesco Ltd. now owns 613,015 shares of the company’s stock valued at $5,959,000 after buying an additional 458,714 shares in the last quarter. XTX Topco Ltd bought a new stake in Replimune Group in the 4th quarter worth approximately $322,000. Virtus Investment Advisers LLC raised its holdings in shares of Replimune Group by 127.0% during the 4th quarter. Virtus Investment Advisers LLC now owns 26,133 shares of the company’s stock worth $254,000 after acquiring an additional 14,622 shares in the last quarter. Finally, SummitTX Capital L.P. bought a new position in shares of Replimune Group during the 4th quarter valued at approximately $1,058,000. Institutional investors own 92.53% of the company’s stock.
About Replimune Group
Replimune Group, Inc is a clinical‐stage biotechnology company focused on developing next‐generation oncolytic immunotherapies for the treatment of solid tumors. The company’s proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses.
Replimune’s lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation.